Aggrenox
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background: Despite improvements in treatment, stroke still carries a high death toll and disability in Asia. Extended-release…
This article reviews randomized control trials (RCT's) published in 2006 of various medications evaluated for stroke patients…
Summary Randomized trials showed greater stroke prevention with extended release dipyridamole in combination with low dose…
Stroke is the third leading cause of death in the US with recurrent events a high likelihood in those who survive an initial…
Aggrenox® is a novel combination of 25 mg of aspirin with 200 mg of sustained release dipyridamole. In a recent large trial (ESPS…
To the Editor:
A new medication,Aggrenox, a formulation of aspirin and extended-release dipyridamole, is being actively…
Stroke is one of the leading causes of death in the United States. The risk of experiencing a recurrent stroke remains elevated…
Aggrenox, launched in Belgium by Boehringer Ingelheim, is a fixed-dose combination of extended-release dipyridamole (200 mg) and…